Aligos Therapeutics (ALGS) Cash & Equivalents (2019 - 2026)
Aligos Therapeutics' (ALGS) quarterly Cash & Equivalents came in at $54.9 million in Q1 2026, down 60.19% YoY from $137.9 million in Q1 2025, and up 199.95% on a QoQ basis from $18.3 million in Q4 2025.
Aligos Therapeutics (ALGS) Cash & Equivalents (2019 - 2026) Analysis & Trends
Aligos Therapeutics (ALGS) has 8 years of Cash & Equivalents data on file, last reported at $54.9 million in Q1 2026.
- Quarterly Cash & Equivalents fell 60.19% year-over-year to $54.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $54.9 million (down 60.19% YoY) and the FY2025 annual result came in at $18.3 million, down 50.53% from the prior year.
- Cash & Equivalents advanced to $54.9 million in Q1 2026, from $18.3 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $137.9 million in Q1 2025 to a low of $18.3 million in Q4 2025.
- A 5-year average of $86.6 million and a median of $86.4 million in 2022 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2023 — Cash & Equivalents jumped 66.82% — and 2024, when it slumped 72.74%.
- Tracing ALGS's Cash & Equivalents over 5 years: stood at $81.3 million in 2022, then jumped by 66.82% to $135.7 million in 2023, then tumbled by 72.74% to $37.0 million in 2024, then plunged by 50.53% to $18.3 million in 2025, then surged by 199.95% to $54.9 million in 2026.
- The last three Cash & Equivalents figures came in at $54.9 million (Q1 2026), $18.3 million (Q4 2025), and $99.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 3.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.72 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.71 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 8.93 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 544.80 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 811.99 Mn |
| 10 | Aligos Therapeutics | 68.90 Mn | 38.45 Mn | - | 30.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 30.40 Mn |
| Mar 31, 2026 | 54.90 Mn |
| Dec 31, 2025 | 18.30 Mn |
| Sep 30, 2025 | 99.10 Mn |
| Jun 30, 2025 | 122.90 Mn |
| Mar 31, 2025 | 137.90 Mn |
| Dec 31, 2024 | 37.00 Mn |
| Sep 30, 2024 | 74.90 Mn |
| Jun 30, 2024 | 94.50 Mn |
| Mar 31, 2024 | 112.70 Mn |
| Dec 31, 2023 | 135.70 Mn |
| Sep 30, 2023 | 70.43 Mn |
| Jun 30, 2023 | 90.83 Mn |
| Mar 31, 2023 | 78.67 Mn |
| Dec 31, 2022 | 81.35 Mn |
| Sep 30, 2022 | 86.44 Mn |
| Jun 30, 2022 | 71.17 Mn |
| Mar 31, 2022 | 104.56 Mn |
| Dec 31, 2021 | 186.82 Mn |
| Sep 30, 2021 | 239.73 Mn |